APA (7th ed.) Citation

YS, H., CY, M., HY, R., CH, C., HH, T., CH, C., . . . CH, Y. (2026). Phenotypic Response Surfaces-Guided Optimization (PRS-OPT) of Propolis-Metformin-Regorafenib Combination Therapy for MASLD-Associated Hepatocellular Carcinoma. Oncology research, 34(6), 25. https://doi.org/10.32604/or.2026.074145

Chicago Style (17th ed.) Citation

YS, Huang, Ma CY, Roan HY, Chiang CH, Tsou HH, Chen CH, Lin YF, Wang HD, and Yuh CH. "Phenotypic Response Surfaces-Guided Optimization (PRS-OPT) of Propolis-Metformin-Regorafenib Combination Therapy for MASLD-Associated Hepatocellular Carcinoma." Oncology Research 34, no. 6 (2026): 25. https://doi.org/10.32604/or.2026.074145.

MLA (9th ed.) Citation

YS, Huang, et al. "Phenotypic Response Surfaces-Guided Optimization (PRS-OPT) of Propolis-Metformin-Regorafenib Combination Therapy for MASLD-Associated Hepatocellular Carcinoma." Oncology Research, vol. 34, no. 6, 2026, p. 25, https://doi.org/10.32604/or.2026.074145.